Tripartite motif containing 26 prevents steatohepatitis progression by suppressing C/EBPδ signalling activation

Article Gastroenterology & Hepatology

Tripartite motif-containing protein 31 confers protection against nonalcoholic steatohepatitis by deactivating mitogen-activated protein kinase kinase kinase 7

Min-Xuan Xu et al.

Summary: TRIM31, a member of the E3 ubiquitin ligases family, has been identified as an efficient endogenous inhibitor of MAP3K7, and may serve as a promising therapeutic target for NASH treatment and associated metabolic disorders.

HEPATOLOGY (2023)

Add to Collection

Article Urology & Nephrology

Association of metabolic dysfunction-associated fatty liver disease with kidney disease

Ting-Yao Wang et al.

Summary: Metabolic dysfunction-associated fatty liver disease (MAFLD) is proposed as a replacement term for non-alcoholic fatty liver disease (NAFLD) to emphasize the role of metabolic dysfunction and provide inclusive diagnostic criteria. MAFLD is associated with chronic kidney disease (CKD) and may increase the risk of CKD.

NATURE REVIEWS NEPHROLOGY (2022)

Add to Collection

Review Cell Biology

RING-finger E3 ligases regulatory network in PI3K/AKT-mediated glucose metabolism

Wenke Wang et al.

Summary: The PI3K/AKT signaling pathway plays a crucial role in glucose metabolism. It directly affects glucose metabolism by phosphorylating enzymes and regulators, and indirectly promotes aerobic glycolysis by increasing glucose transporters and glycolytic enzymes. The RING-finger adaptor has been found to have an important role in PI3K/AKT signaling, but there is currently no comprehensive review on its role in glucose metabolism.

CELL DEATH DISCOVERY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis

Catherine Frenette et al.

Summary: Emricasan was found to be safe but ineffective in treating decompensated NASH cirrhosis in a double-blind, placebo-controlled study with 217 participants. This study may provide guidance for future clinical trials in patients with decompensated cirrhosis related to non-alcoholic steatohepatitis.

JOURNAL OF HEPATOLOGY (2021)

Add to Collection

Letter Medicine, General & Internal

Highlighting obesity as a risk factor for endometrial cancer

Andrea N. Simpson et al.

CANADIAN MEDICAL ASSOCIATION JOURNAL (2021)

Add to Collection

Article Clinical Neurology

Adiposity and Outcome After Ischemic Stroke Obesity Paradox for Mortality and Obesity Parabola for Favorable Functional Outcomes

Zuolu Liu et al.

Summary: This study examined the relationship between body mass index and outcomes in patients with acute ischemic stroke, revealing the obesity paradox. Different outcomes such as survival, disability, and stroke-related quality of life were analyzed.

STROKE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Deubiquitinase USP39 and E3 ligase TRIM26 balance the level of ZEB1 ubiquitination and thereby determine the progression of hepatocellular carcinoma

Xiaomei Li et al.

Summary: The deubiquitinase USP39 promotes HCC progression by inhibiting ZEB1 degradation, while the E3 ligase TRIM26 inhibits HCC cell proliferation and migration by promoting ZEB1 degradation through ubiquitination. USP39 and TRIM26 interact in an antagonistic pattern to balance ZEB1 ubiquitination levels and control HCC progression. This novel mechanism may offer new therapeutic strategies for inhibiting HCC development.

CELL DEATH AND DIFFERENTIATION (2021)

Add to Collection

Article Medicine, Research & Experimental

The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis

Manal F. Abdelmalek et al.

Summary: Pegbelfermin (PGBF), a human fibroblast growth factor 21 analog, is being evaluated for its therapeutic effects on patients with NASH in the FALCON 1 and 2 studies. The primary focus is on improvement in fibrosis and progression of NASH in patients with advanced fibrosis.

CONTEMPORARY CLINICAL TRIALS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis

Roser Pinyol et al.

Summary: This study revealed higher rates of ACVR2A mutations (10%) in NASH-related hepatocellular carcinoma (HCC), along with a novel mutational signature that distinguishes NASH-HCC from HCCs of other etiologies.

JOURNAL OF HEPATOLOGY (2021)

Add to Collection

Article Cell Biology

TRIM26 Induces Ferroptosis to Inhibit Hepatic Stellate Cell Activation and Mitigate Liver Fibrosis Through Mediating SLC7A11 Ubiquitination

Yiming Zhu et al.

Summary: In this study, the researchers found that TRIM26 promotes HSCs ferroptosis through mediating the ubiquitination of SLC7A11, thereby suppressing liver fibrosis. The targeted suppression of SLC7A11 by TRIM26 could be a novel therapeutic strategy for liver fibrosis.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

TRIM26 positively regulates the inflammatory immune response through K11-linked ubiquitination of TAB1

Jian Zhao et al.

Summary: The study reveals that TRIM26 positively regulates TAK1 activation by ubiquitinating its binding partner TAB1. Trim26 deficiency reduces the induction of inflammatory cytokines, protecting mice from septic shock and attenuating the severity of colitis.

CELL DEATH AND DIFFERENTIATION (2021)

Add to Collection

Review Chemistry, Medicinal

Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease

Julia M. Fraile et al.

Summary: Non-alcoholic steatohepatitis (NASH) is a common chronic liver condition with no FDA-approved therapies. Despite a growing market and clinical need, finding effective drugs has been challenging. Several drug candidates are in late-stage clinical trials, but the complex pathophysiology of NASH may require drug combination and targeting of different stages of the disease.

DRUG DESIGN DEVELOPMENT AND THERAPY (2021)

Add to Collection

Article Cell Biology

CEBPD Potentiates the Macrophage Inflammatory Response but CEBPD Knock-Out Macrophages Fail to Identify CEBPD-Dependent Pro-Inflammatory Transcriptional Programs

C. Arnold Spek et al.

Summary: The impact of C/EBP delta on cytokine production and macrophage function varies depending on macrophage subtypes and LPS concentrations. Knocking out C/EBP delta may trigger compensatory transcriptional activity, leading to significant differences in transcriptional programs related to overall macrophage biology.

CELLS (2021)

Add to Collection

Review Gastroenterology & Hepatology

Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis

Alessandro Mantovani et al.

Summary: Studies have shown a significant association between non-alcoholic fatty liver disease (NAFLD) and increased risk of cardiovascular disease (CVD) incidence. The risk of fatal or non-fatal CVD events is moderately increased with NAFLD, and this risk escalates with the severity of NAFLD, particularly with higher fibrosis stages. These findings suggest that NAFLD may be an independent risk factor for CVD morbidity and mortality.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Article Acoustics